Sarah Cannon Research Institute
Annastasia (Aja) Hyde currently serves as the Associate Director of Therapeutic Development at Sarah Cannon Research Institute, a position held since June 2023. Prior to this, Aja worked at Sarah Cannon from July 2017 to June 2023, advancing from Clinical Lab Data Analyst to Senior Program Manager. Aja's experience also includes a postdoctoral fellowship at Vanderbilt University from June 2014 to June 2017, and graduate and teaching assistant roles at the University of Nebraska-Lincoln from January 2010 to June 2014. Aja earned a Ph.D. in Biochemistry from the University of Nebraska-Lincoln and a Bachelor of Science in Biochemistry from Creighton University.
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.